Protein Sciences is calling on its home state to kickstart its entry into the flu vaccine sector by purchasing its shot. The Connecticut-based biotech won approval for its flu vaccine last year but it faces competition from GlaxoSmithKline ($GSK), Sanofi ($SNY) and the other established giants of the market. Protein Sciences' vaccine differs from these rivals because it is made using an insect cell-based production process. Article